Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists

被引:36
|
作者
Randall, Patrick A. [1 ]
Nunes, Eric J. [1 ]
Janniere, Simone L. [1 ]
Stopper, Colin M. [1 ]
Farrar, Andrew M. [1 ]
Sager, Thomas N. [2 ]
Baqi, Younis [3 ]
Hockemeyer, Joerg [3 ]
Mueller, Christa E. [3 ]
Salamone, John D. [1 ]
机构
[1] Univ Connecticut, Dept Psychol, Storrs, CT 06269 USA
[2] H Lundbeck & Co AS, Pharmacol Target Res, DK-2500 Copenhagen, Denmark
[3] Univ Bonn, Inst Pharmazeut, Pharma Zentrum Bonn, D-5300 Bonn, Germany
关键词
Activation; Anergia; Psychomotor slowing; Depression; Dopamine; Parkinsonism; SCHEDULE-CONTROLLED BEHAVIOR; D-AMPHETAMINE; RECEPTOR ANTAGONISTS; NUCLEUS-ACCUMBENS; SYMPATHOMIMETIC AMINES; LOCOMOTOR SUPPRESSION; DECISION-MAKING; MSX-3; REVERSES; CAFFEINE; DOPAMINE;
D O I
10.1007/s00213-011-2198-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Adenosine A(2A) antagonists can reverse many of the behavioral effects of dopamine antagonists, including actions on instrumental behavior. However, little is known about the effects of selective adenosine antagonists on operant behavior when these drugs are administered alone. The present studies were undertaken to investigate the potential for rate-dependent stimulant effects of both selective and nonselective adenosine antagonists. Six drugs were tested: two nonselective adenosine antagonists (caffeine and theophylline), two adenosine A(1) antagonists (DPCPX and CPT), and two adenosine A(2A) antagonists (istradefylline (KW6002) and MSX-3). Two schedules of reinforcement were employed; a fixed interval 240-s (FI-240 sec) schedule was used to generate low baseline rates of responding and a fixed ratio 20 (FR20) schedule generated high rates. Caffeine and theophylline produced rate-dependent effects on lever pressing, increasing responding on the FI-240 sec schedule but decreasing responding on the FR20 schedule. The A(2A) antagonists MSX-3 and istradefylline increased FI-240 sec lever pressing but did not suppress FR20 lever pressing in the dose range tested. In fact, there was a tendency for istradefylline to increase FR20 responding at a moderate dose. A(1) antagonists failed to increase lever pressing rate, but DPCPX decreased FR20 responding at higher doses. These results suggest that adenosine A(2A) antagonists enhance operant response rates, but A(1) antagonists do not. The involvement of adenosine A(2A) receptors in regulating aspects of instrumental response output and behavioral activation may have implications for the treatment of effort-related psychiatric dysfunctions, such as psychomotor slowing and anergia in depression.
引用
收藏
页码:173 / 186
页数:14
相关论文
共 50 条
  • [41] 5-Substituted 2-benzylidene-1-tetralone analogues as A1 and/or A2A antagonists for the potential treatment of neurological conditions
    van Rensburg, H. D. Janse
    Terre'Blanche, G.
    van der Walt, M. M.
    Legoabe, L. J.
    BIOORGANIC CHEMISTRY, 2017, 74 : 251 - 259
  • [42] Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
    Xu, K
    Bastia, E
    Schwarzschild, M
    PHARMACOLOGY & THERAPEUTICS, 2005, 105 (03) : 267 - 310
  • [43] Adenosine A2A Antagonists in Parkinson's Disease: What's Next?
    Hickey, Patrick
    Stacy, Mark
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2012, 12 (04) : 376 - 385
  • [44] The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists
    Lila T. Worden
    Mona Shahriari
    Andrew M. Farrar
    Kelly S. Sink
    Jörg Hockemeyer
    Christa E. Müller
    John D. Salamone
    Psychopharmacology, 2009, 203 : 489 - 499
  • [45] Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A1 and A2A receptor activation
    Cunha, Mauricio P.
    Pazini, Francis L.
    Rosa, Julia M.
    Ramos-Hryb, Ana B.
    Oliveira, Agatha
    Kaster, Manuella P.
    Rodrigues, Ana Lucia S.
    PURINERGIC SIGNALLING, 2015, 11 (02) : 215 - 227
  • [46] The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant
    LeWitt, Peter A.
    Aradi, Stephen D.
    Hauser, Robert A.
    Rascol, Olivier
    PARKINSONISM & RELATED DISORDERS, 2020, 80 : S54 - S63
  • [47] Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens.: Effects of chronic caffeine exposure
    Quarta, D
    Ferré, S
    Solinas, M
    You, ZB
    Hockemeyer, J
    Popoli, P
    Goldberg, SR
    JOURNAL OF NEUROCHEMISTRY, 2004, 88 (05) : 1151 - 1158
  • [48] Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges
    Franco, Rafael
    Navarro, Gemma
    FRONTIERS IN PSYCHIATRY, 2018, 9
  • [49] Substituted 4-phenylthiazoles: Development of potent and selective A1, A3 and dual A1/A3 adenosine receptor antagonists
    Abdelrahman, Aliaa
    Yerande, Swapnil G.
    Namasivayam, Vigneshwaran
    Klapschinski, Tim A.
    Alnouri, Mohamad Wessam
    El-Tayeb, Ali
    Mueller, Christa E.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 186